N-methyl-4-(naphthalen-2-yl)-1,3-thiazol-2-amine | 21331-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-methyl-4-(naphthalen-2-yl)-1,3-thiazol-2-amine
• 英文别名: N-methyl-4-naphthalen-2-yl-1,3-thiazol-2-amine
• CAS: 21331-44-2
• 化学式: C₁₄H₁₂N₂S
• mdl: MFCD17021454
• 分子量: 240.329
• InChiKey: MJSVZUUDBUUQDH-UHFFFAOYSA-N

物化性质

• 熔点：
  123-124 °C
• 沸点：
  415.3±43.0 °C(Predicted)
• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-methyl-4-(naphthalen-2-yl)-1,3-thiazol-2-amine 、 苯酐 以 吡啶 为溶剂， 生成 2-[4-(naphthalin-2-yl)-thiazol-2-yl-N-methyl-aminocarbonyl]-benzoic acid
  参考文献：
  名称：

  Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production

  摘要：

  本申请涉及使用一般式R1—A—B—R2(I)的羧酸衍生物，其中R1、R2、A和B如权利要求1所定义，其异构体和盐，特别是生理学上可接受的盐，具有对端粒酶的抑制作用，其制备过程，含有这些化合物的制药组合物以及其用途和制备方法。

  公开号：

  US20030055263A1
• 作为产物：
  描述：

  N-甲硫脲 、 2-溴代-2-乙酰基萘 以 水 为溶剂， 反应 2.0h， 以89%的产率得到N-methyl-4-(naphthalen-2-yl)-1,3-thiazol-2-amine
  参考文献：
  名称：

  环境温度下无催化剂高效合成水中的2-氨基噻唑

  摘要：

  已经描述了一种在不添加任何催化剂或共有机溶剂的情况下在水中合成取代的2-氨基噻唑的高效且简便的方法。该反应在环境温度下进行，并且产物以优异的分离产率得到。所开发的方案已成功应用于抗炎药Fanetizole的制备。

  DOI：

  10.1016/j.tet.2008.03.082

文献信息

• INHIBITION OF CELL PROLIFERATION
  申请人：University of South Florida

  公开号：US20140221658A1

  公开（公告）日：2014-08-07

  The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC 50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
• US7442554B2
  申请人：——

  公开号：US7442554B2

  公开（公告）日：2008-10-28
• US8642278B2
  申请人：——

  公开号：US8642278B2

  公开（公告）日：2014-02-04
• US9656953B2
  申请人：——

  公开号：US9656953B2

  公开（公告）日：2017-05-23
• [EN] INHIBITION OF CELL PROLIFERATION<br/>[FR] INHIBITION OF CELL PROLIFERATION
  申请人：UNIV SOUTH FLORIDA

  公开号：WO2007062222A2

  公开（公告）日：2007-05-31

  [EN] The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC₅₀ values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.
  [FR] The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC₅₀ values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.